CMS Announces Selection of Drugs for Third Cycle of the Medicare Drug Price Negotiation Program

February 12, 2026

Medicare

On Jan. 27, CMS announced the 15 drugs selected for the third cycle of negotiations under the Medicare Drug Price Negotiation Program. This is the first negotiation cycle for which Part B drugs were eligible to be selected in addition to Part D drugs. The drugs selected treat conditions such as asthma, Type-2 diabetes, arthritis, and cancer: Anoro Ellipta, Biktarvy, Botox/Botox Cosmetic, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Trulicity, Verzenio, Xeljanz/Xeljanz XR, and Xolair.

According to CMS, these drugs accounted for $27 billion in total expenditures under Medicare Part B and Part D, or about 6% of total expenditures under Medicare Part B and Part D, between Nov. 1, 2024 and Oct. 31, 2025. The negotiation period will continue through Nov. 1, with CMS expected to publish any negotiated maximum fair prices (MFPs) by Nov. 30. The new MFPs will go into effect on Jan. 1, 2028.

legislation

Virginia and Hawaii Introduce PDAB Legislation

The Virginia Senate introduced a bill to establish a Prescription Drug Affordability Board (PDAB) to review drugs with a wholesale acquisition cost (WAC) of $60,000 or more per year or a WAC increase of $3,000 or more in any 12-month period. For drugs deemed to cause an affordability challenge, the legislation authorizes the PDAB to […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

Solutions

AHIP Shares Update on Plan Progress to Simplify Prior Authorization

AHIP shared progress on the voluntary, multi-year commitments made by AHIP, BCBSA, and leading health plans (including Cigna Healthcare) to streamline and simplify prior authorization. Health plans serving nearly 270 million Americans are participating in this initiative. The 2026 commitments took effect on Jan. 1 and include: reducing the scope of claims subject to prior […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

legislation

DOL Issues Proposed Rule on Improving Transparency into PBM Fees

Pursuant to President Trump’s Executive Order “Lowering Drug Prices by Once Again Putting Americans First,” the Department of Labor’s (DOL’s) Employee Benefits Security Administration (EBSA) issued a proposed rule that would require providers of PBM services and affiliated entities of brokerage and consulting services to disclose direct and indirect compensation to their self-funded ERISA fiduciary […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

You may also like